Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05331625

Understanding Quality of Life Among Patients With Cancer Receiving Palliative Care

This randomized controlled trial will assess the effects on quality of life of two approaches to symptom management among new patients referred to a palliative care oncology clinic.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Cancer Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be a new patient at an outpatient palliative care clinic
  • Resident of Pennsylvania
  • Over 18 years of age

Exclusion criteria

  • Prior use of certain symptom focused therapies
  • Currently pregnant

Treatment and study plan

Offering Additional Resources to Promote Symptom Management

Behavioral

Participants will be offered additional resources to promote symptom management.

Primary outcomes

  1. Quality of Life - McGill Quality of Life Questionnaire

    Time frame: Baseline - 16 weeks

    Quality of life will be measured through the McGill Quality of Life Questionnaire Revised (MQOL-R). The questionnaire is 15 questions assessing overall and specific areas of quality of life.

Secondary outcomes

  1. Feasibility of Accessing Additional Resources for Symptom Management

    Time frame: Baseline - 16 weeks

    Feasibility will be measured by whether participants accessed the additional resources for symptom management.

  2. Acceptability of Accessing Additional Resources for Symptom Management

    Time frame: Baseline - 16 weeks

    Acceptability will be measured by whether participants accessed the additional resources for symptom management.

  3. Symptom Severity

    Time frame: Baseline - 16 weeks

    Symptom severity will be measured through the Edmonton Symptom Assessment System (ESAS). The survey is 10 questions assessing the severity of pain, nausea, depression, etc. on a 0 to 10 scale-in which a 0 representing best possible state/symptom absence and a 10 representing worst possible state.

  4. Medication Use

    Time frame: Baseline - 16 weeks

    Medication use will be measured through a medication diary created for the study. The medication diary asks participants about recent medications, amounts, and dosages.

  5. Hospital-Free Days

    Time frame: Baseline - 16 weeks

    Hospital-free days will be measured through examination of participant's electronic health record.

  6. Mortality

    Time frame: Baseline - 16 weeks

    Mortality will be measured through examination of participant's electronic health record.

Sponsors and collaborators

Lead sponsor

Abramson Cancer Center at Penn Medicine

Other

Registry information

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Apr 15, 2022
Registry last updated
Jul 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.